Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of <scp>HIV</scp>‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists
Elizabeth M Sherman, Allison L. Agwu, Juan Ambrosioni, Georg M. N. Behrens, Carolyn Chu, Lauren F. Collins, Humberto R. Jimenez, David E. Koren, Leslie McGorman, Nancy N. Nguyen, Melanie R. Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K. Scarsi, Gary F. Spinner, Alice Tseng, J. D. Young, Melissa E. Badowski
Abstract
Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.